Trypanothione reductase is a key enzyme in the trypanothione-based redox metabolism of pathogenic trypanosomes. Because this system is absent in humans, being replaced with glutathione and glutathione reductase, it offers a target for selective inhibition. The rational design of potent inhibitors requires accurate structures of enzyme-inhibitor complexes, but this is lacking for trypanothione reductase. We therefore used quinacrine mustard, an alkylating derivative of the competitive inhibitor quinacrine, to probe the active site of this dimeric flavoprotein. Quinacrine mustard irreversibly inactivates Trypanosoma cruzi trypanothione reductase, but not human glutathione reductase, in a time-dependent manner with a stoichiometry of two inhibitors bound per monomer. The rate of inactivation is dependent upon the oxidation state of trypanothione reductase, with the NADPH-reduced form being inactivated significantly faster than the oxidized form. Inactivation is slowed by clomipramine and a melarsen oxide-trypanothione adduct (both are competitive inhibitors) but accelerated by quinacrine. The structure of the trypanothione reductase-quinacrine mustard adduct was determined to 2.7 Å, revealing two molecules of inhibitor bound in the trypanothione-binding site. The acridine moieties interact with each other through -stacking effects, and one acridine interacts in a similar fashion with a tryptophan residue. These interactions provide a molecular explanation for the differing effects of clomipramine and quinacrine on inactivation by quinacrine mustard. Synergism with quinacrine occurs as a result of these planar acridines being able to stack together in the active site cleft, thereby gaining an increased number of binding interactions, whereas antagonism occurs with nonplanar molecules, such as clomipramine, where stacking is not possible.
Parasitic protozoa of the order Kinetoplastida are the causative agents of several serious tropical diseases. These comprise Chagas' disease (caused by Trypanosoma cruzi), sleeping sickness (by Trypanosoma brucei spp.), and the leishmaniases, caused by parasites of the genus Leishmania (1) . Despite these infections causing in excess of 120,000 deaths per annum (2) , comparatively little research effort is directed toward these diseases. As a result of this disregard, current chemotherapy is poor and treatment failure is common, because of widespread drug resistance and severe side effects.
The development of new drugs to treat these diseases would be aided by the discovery of compounds that interfere with processes that are essential to the parasites but absent from their human hosts. A promising target for the design of such inhibitors is the thiol metabolism of these protozoa. This is dependent upon trypanothione (T [SH] 2 or N 1 ,N 8 -bis(glutathionyl)spermidine), 1 a low molecular mass dithiol that is absent from humans but used by the kinetoplastids to maintain their intracellular redox balance (3) . This thiol acts to counteract environmental stress through a variety of enzymatic and nonenzymatic reactions and has been implicated in acquired resistance to chemotherapeutic agents (4, 5) . Many of these protective reactions oxidize T[SH] 2 to trypanothione disulfide (T[S] 2 ), which is then recycled back to T[SH] 2 by trypanothione reductase (TryR), an NADPH-dependent disulfide oxidoreductase. TryR is thought to be the key enzyme in the redox metabolism of these organisms, acting as the sole route of reducing equivalents from the NADP ϩ /NADPH couple to thiolcontaining species (6) . The fundamental importance of TryR activity to parasite survival has been demonstrated by both genetic manipulations and the discovery that the targets of several of the current antiprotozoal drugs are enzymes involved in trypanothione metabolism (7) (8) (9) .
In contrast, in the mammalian host, the major low molecular mass thiol is glutathione, with the enzyme glutathione reductase acting to reduce glutathione disulfide (10) . Although TryR and glutathione reductase are closely related and show ϳ40% sequence identity (11) , each enzyme is highly specific for its respective substrate (12) . The three-dimensional structure of a T. cruzi TryR-T[S] 2 complex has been solved, demonstrating that this specific recognition of T[S] 2 is mainly determined by the negative charge and hydrophobic surfaces within the large TryR active site (13) . The marked differences between the TryR and glutathione reductase active sites therefore make selective inhibition possible, and a large number of TryR-specific inhibitors have already been identified (14) . Many of these TryR inhibitors are tricyclic compounds that are thought to interact * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and structure factors (code 1GXF) with the hydrophobic polyamine-binding site within the active site (15) . One of the best characterized of these inhibitors is quinacrine, an acridine derivative that is an effective and selective inhibitor of TryR (16, 17) .
The development of more potent TryR inhibitors would be facilitated by high resolution structures of TryR-inhibitor complexes. Although one structure of the T. cruzi TryR-quinacrine complex has been solved, the resulting model was unfortunately of low resolution and only showed a single quinacrine molecule bound in one of the four active sites that are present in the asymmetric unit (18) . This model is inconsistent with subsequent studies that showed that enzyme inhibition is produced by multiple quinacrine molecules binding to the enzyme (19) . These conflicting data encouraged us to extend these studies using quinacrine mustard (QM) as a high affinity probe to characterize the quinacrine-binding sites in TryR. This is an alkylating derivative of quinacrine in which the quinacrine diethylamino group has been replaced by the reactive bis-(2-chloroethyl)amino mustard group (Fig. 1) . Here we show that QM is an active site-directed irreversible inhibitor of TryR. A structure of the resulting covalent TryR-QM adduct was obtained that demonstrated that two QM molecules stack in the TryR active site. The kinetics of the inactivation reaction were studied in detail, and these data were found to be entirely consistent with the crystallographic model of the interactions between QM ligands. These results therefore provide a structural explanation for the multisite inhibition of TryR by quinacrine (19) with implications for the future design of tight binding and irreversible inhibitors.
EXPERIMENTAL PROCEDURES
Materials-Recombinant T. cruzi TryR was purified as previously described (20) . Glutathione reductase was purified to homogeneity from outdated human blood donations (21) . Trypanothione was purchased from Bachem. Quinacrine and QM were obtained from Sigma. Cosubstrate NADPH was purchased from Melford Laboratories. All other reagents were standard commercial products and of the highest available purity.
Trypanothione Reductase Assay-The concentrations of stock solutions of T[S] 2 were determined by titration with TryR and determining the change in NADPH absorption at 340 nm, following total substrate depletion. TryR was quantified spectrophotometrically using the absorption coefficient of 11.3 mM Ϫ1 cm Ϫ1 at 464 nm (22) . TryR activity was assayed at 27°C using either a Shimadzu UV-2401 or a UV-1601 temperature-controlled spectrophotometer in 1-ml assays containing 40 mM Na-HEPES, pH 7.5, 1 mM EDTA, 150 M NADPH, and 100 M T[S] 2 unless stated otherwise.
Quinacrine Mustard Inactivation Kinetics-Inactivation reactions were carried out in assay buffer containing 40 mM Na-HEPES, pH 7.5, 1 mM EDTA at room temperature, using 1 M TryR or NADPH-reduced TryR and varying amounts of QM. The residual activity of inactivation mixtures was determined at various time points by initiating TryR assays with 10-l samples (100-fold dilution) of this inactivation mixture. The resulting data were then fitted using nonlinear regression to a single exponential decay function using the program GraFit (Erithacus Software Limited) written by R. J. Leatherbarrow. All of the activities are expressed as percentages of the activity of a parallel control lacking QM.
Measurement of QM-TryR Stoichiometry-NADPH-reduced TryR (1 M) was inactivated with 10 M QM, and the aliquots were removed at intervals. Inactivation was quenched by adding 2-mercaptoethanol to a final concentration of 25 mM, and the residual activities were determined as described above. Trichloroacetic acid was added to each sample (20% (w/v) final concentration) and incubated for 2 h at 4°C. Denatured protein was recovered by centrifugation (10,000 ϫ g for 10 min at 4°C) and washed twice with acetone (at Ϫ20°C) to remove residual QM and FAD. The protein pellet was then digested with proteinase K (0.1 mg ml Ϫ1 ) in 40 mM HEPES, pH 7.5, 1 mM EDTA for 4 h at 56°C, and covalently bound QM was quantified spectrophotometrically using a millimolar absorption coefficient of 7.9 mM Ϫ1 cm Ϫ1 at 424 nm. 2 was produced from T[S] 2 by reduction with a 1.5-fold excess of Tris-(2-carboxyethyl)phosphine dissolved in Buffer A (10 mM ammonium acetate, pH 7.8). The melarsen oxide-trypanothione adduct (Mel T) was prepared by mixing 10 mol of T[SH] 2 with 10 mol of melarsen oxide in 0.85 ml of buffer A. The resulting mixture was then applied at 1 ml min Ϫ1 to a 1 ml (0.5 ϫ 5 cm) Amersham Biosciences Mono S HR 5/5 cation exchange column that had been pre-equilibrated with 5 column volumes of buffer A. After washing the column with 5 column volumes of buffer A, Mel T was eluted by a linear gradient of 0 -100% buffer B (500 mM ammonium acetate, pH 7.8). Under these conditions, Mel T eluted at ϳ100 mM ammonium acetate. The product was then lyophilized, redissolved in 1 mM HCl, and stored at Ϫ20°C
Synthesis of the Adduct of Melarsen Oxide with Dihydrotrypanothione (Mel T)-T[SH]
Mass Spectrometric Analysis of QM-TryR Adduct-A sample of TryR (20 M) was reduced with NADPH (150 M) mixed with 100 M QM, and inactivation was monitored by enzymatic assay as described above. When 95% inactivation had been achieved, the reaction was stopped by addition of 2-mercaptoethanol to a final concentration of 25 mM. Another control sample was run in parallel without QM. Both samples were dialyzed extensively against water, diluted 2-fold with 40 mM NH 4 HCO 3 and digested with trypsin (6.25 g ml Ϫ1 ) overnight at 30°C. Aliquots (1 l) were spotted onto a matrix-assisted laser desorption ionization sample target and allowed to dry before addition of 1 l of matrix (10 mg ml Ϫ1 ␣-cyano-4-hydroxycinnamic acid in 50:50 water acetonitrile, 0.1% (w/v) trifluoroacetic acid). The dried samples were then analyzed by matrix-assisted laser desorption ionization time-offlight mass spectrometry in reflectron mode. The peptide masses identified were then compared with a theoretical digest of the protein.
Crystallographic Methods-A sample of 1 mg of TryR (20 nmol of active site) in a volume of 1.2 ml was reduced with 500 nmol of NADPH and inactivated with 40 nmol of QM. Upon complete inactivation, the reaction was quenched by the addition of 2-mercaptoethanol to 10 mM, and the protein was exchanged into 100 mM (Na ϩ ) malate pH 6 and concentrated to 15 mg ml Ϫ1 . Crystallization experiments concentrated on previously reported conditions (23), namely 13 mg ml Ϫ1 TryR-QM adduct in Na ϩ malate buffer at pH 6.0 and ϳ20% (w/v) polyethylene glycol 8000 as a precipitant. Only one suitable crystal was obtained, and the rest were twinned or too small for use. Because we were unable to identify cryoprotection conditions for these TryR crystals, the sample was placed in a capillary with a drop of mother liquor for use in diffraction experiments. The data were collected on BM14 at the European Synchrotron Radiation Facility at room temperature from a single crystal (approximate dimensions 0.05 ϫ 0.05 ϫ 0.3 mm) with a MAR image plate as detector, and the x-ray wavelength was set at 1.00 Å. The space group is P4 3 with unit cell dimensions of a ϭ 93.1 Å, c ϭ 156.6 Å, and the crystal was found to be isomorphous with those previously obtained of the enzyme by itself or in complex with substrate (13, 23) . All data were processed, reduced, and scaled using the HKL suite of programs (24) and then analyzed using the CCP4 software package (25) . Four percent of the diffraction data, 1228 reflections, were reserved for cross-validation using the R free parameter (26) . The data measurements ceased when radiation damage became evident, which limited the quantity of data that could be obtained; the relevant statistics are provided in Table I .
The asymmetric unit contains a functional homodimer, the monomers of which were placed by rigid body refinement using REFMAC (27) . Subsequent positional and temperature factor refinement employing tight noncrystallographic symmetry restraints, a bulk solvent correction, and anisotropic scaling produced a model suitable for rebuilding in the graphics program O (28) . Several rounds of rebuilding, the conservative addition of ordered solvent molecules and refinement produced a model with R and R free values less than 0.30. At this point interpretation of omit electron density in each active site was made using the coordinates for quinacrine (reference code QUIANC10, (29) obtained from the Cambridge Structural Database) (30) . Geometric restraints for refinement were generated taking into account the likely 
Structure of a Trypanothione Reductase Quinacrine Complex
protonation state at pH 6.0. Although the electron density clearly indicates the orientation of the tricyclic ring systems, it is not of sufficient clarity to distinguish between S-and R-isomers at C-19, both of which are present in the Cambridge Structural Database entry QUIANC10. Accordingly, the S-isomer was arbitrarily chosen for model building. Minimal residual difference density and temperature factors consistent with those of the rest of the structure were obtained by refining the quinacrine moieties at half-occupancy. The final model contains a TryR dimer, four quinacrine moieties, two FAD molecules, one maleic acid, and 53 ordered water molecules. The average temperature factor for all atoms is consistent with the Wilson thermal parameter derived from the diffraction data processing. The Ramachandran analysis (31, 32) indicated that 99.7% of the residues are in a favorable conformation. Additional experimental details are presented in Table I .
RESULTS

Reaction of Quinacrine Mustard with Trypanothione Reductase-Both oxidized (E) and NADPH-reduced (EH 2 ) forms of
TryR show time-dependent inactivation by 20 M QM (Fig. 2) . This effect was specific for TryR because exposure of reduced human glutathione reductase to 100 M QM for 30 min did not cause any inhibition. Inactivation can be rapidly quenched, but not reversed, by the addition of a large excess of 2-mercaptoethanol to remove any unreacted inhibitor ( Fig. 2A, arrow) . Moreover, inactivation could not be reversed by dilution of the enzyme-inhibitor complex or by extensive dialysis (not shown). However, QM-inactivated TryR could be readily visualized under ultraviolet light in SDS-PAGE gels because of the intense fluorescence of the acridine moiety (Fig. 3) . In addition to a fluorescent band at 55 kDa corresponding to the TryR monomer, a faint band at 110 kDa is visible in NADPH-reduced samples, suggesting that a minor amount of cross-linking between subunits of the native homodimer also occurs. Together these findings indicate that inactivation involves covalent modification of the enzyme.
Loss of TryR enzyme activity follows pseudo-first order kinetics for both E and EH 2 forms of the enzyme. Inactivation of the EH 2 form is about 8-fold faster than that of the E form ( Fig.  2A) , suggesting that the sulfydryl groups of the redox-active Cys 53 and/or Cys 58 in the active site could be a preferential target for alkylation. To test this possibility we examined the effects of competitive inhibitors of the T[S] 2 -binding site on the kinetics of inactivation (Fig. 2B) . Mel T, a conjugate of T[SH] 2 and melarsen oxide, is a competitive inhibitor of TryR from T. brucei with a K i value of 9 M (33). Under our experimental conditions, Mel T was found to be a linear competitive inhibitor of T. cruzi TryR (K i ϭ 15.5 Ϯ 0.8 M). As shown in Fig. 2B , Mel T protects the EH 2 form of the enzyme from inactivation by QM. The pseudo-first order rate constants for inactivation of EH 2 enzyme in the presence (kЈ obs ϭ 0.072 Ϯ 0.004 min Ϫ1 ) and absence (k obs ϭ 0.32 Ϯ 0.03 min Ϫ1 ) of Mel T (i ϭ 40 M) were fitted to the following equation, which describes protection by a simple competitive inhibitor (34) .
This yielded a K i for Mel T of 12 M, in good agreement with the directly determined value of 15.5 M. This result suggests that QM alkylates TryR within the T[S] 2 -binding site.
Stoichiometry and Sites of Alkylation by Quinacrine
Mustard-To determine the stoichiometry of the inactivation process, samples of TryR were reduced with NADPH and exposed to QM for different time intervals, the reaction was quenched by the addition of excess 2-mercaptoethanol, and the resulting samples were assayed for residual activity. Alkylated protein was precipitated with trichloroacetic acid, washed to remove unbound QM, and redissolved by digestion with proteinase K for spectrophotometric determination of bound QM (Fig. 4) . The number of moles of QM bound per mole active site shows a limit of 1.7 Ϯ 0.2, consistent with 2 mol of QM being covalently bound per mole of inactive TryR monomer. Moreover, because 50% inactivation is associated with 1 mol of QM bound per total monomer, it can be deduced that the majority of the inactive EH 2 form of the enzyme has 2 mol of QM bound per monomer.
To determine the sites of alkylation, protein samples were inactivated as above, quenched with mercaptoethanol, dialyzed, and digested with trypsin. The resulting matrix-assisted laser desorption ionization time-of-flighty mass spectrometry spectra clearly showed that the peptide fragment C (residues 32-61, 3041.6 Da) bearing Cys 53 and Cys 58 disappeared on incubation with QM, indicating that this fragment was undergoing modification. However, although a number of new peptide fragments were observed, we were unable to unambiguously identify a predicted product (e.g. monoalkylated peptide C ϩ QM Ϫ HCl, mass ϭ 3774 Da; bis-alkylated peptide C ϩ QM Ϫ 2HCl, mass ϭ 3437 Da; or a mixed adduct between peptide C from TryR, QM, and 2-mercaptoethanol, mass ϭ 3516 Da). Although modification of this peptide could have suppressed its ionization, another possible explanation for this anomalous behavior is discussed below.
Inhibition Kinetics of Quinacrine Mustard-Inactivation of TryR by QM is also dose-dependent for the E and EH 2 forms of the enzyme (Fig. 5, A and B, respectively) . Formation of the QM-TryR covalent adduct could either proceed as a simple bimolecular reaction or through a reversible binary complex. The difference between a general chemical modifier and an active site-directed irreversible inhibitor is that the latter can form significant amounts of dissociable complex with enzyme (EI) prior to irreversible covalent modification of the enzyme (E*I) as shown in the following scheme (35) .
The apparent rate of irreversible inhibition (k obs ) is described by the following equation, where K i is the dissociation constant for QM, and k 2 is the rate constant for conversion of EI to E*I. This equation takes the same form as the Michaelis-Menten equation, giving a rectangular hyperbola when k obs is plotted against inhibitor concentration (i) (36, 37) .
from which the "specificity constant for inhibition" (k 2 /K i ) can be determined. In the oxidized (E form) of the enzyme, a plot of (Fig. 5C, open circles) , indicating that a reversible TryR-QM complex is formed prior to irreversible chemical modification of the enzyme. Fitting the data to the above equation yields an apparent K i of 41 Ϯ 8 M and k 2 of 0.69 Ϯ 0.09 min
Assuming that the residue(s) alkylated in the E form is also available for alkylation in the EH 2 form, subtraction of the inactivation rate present in the E form from the EH 2 form gives the kinetics of inactivation at the redox-active cysteine site (Fig. 5C, diamond  symbols) . This yields an apparent K i of 36 Ϯ 8 M and k 2 of 0.58 Ϯ 0.08 min
, which is 17-fold faster than for the E form of the enzyme.
Protection and Acceleration of QM Inhibition by Tricyclic
Inhibitors-The observation that an EI complex is formed as an intermediate in the reaction between the EH 2 form of TryR and QM suggests that inactivation could be prevented by competition with quinacrine. However, when increasing concentrations of quinacrine were coincubated with NADPH-reduced TryR and 10 M QM, the rate of inactivation was initially increased over that produced by QM alone (Fig. 6A, open circles) . This effect was greatest at a quinacrine to QM ratio of 2.5:1, producing a 1.4-fold increase in the rate of TryR inactivation. Interestingly, this effect decreased when higher quinacrine concentrations were used. In contrast, no evidence of any rate enhancement was observed for the TryR incubated in the absence of NADPH (Fig. 6A, closed circles) . These data were fitted to Equation 1 by nonlinear regression using the explicit errors for each net k obs , yielding a K i of 208 Ϯ 45 M. This result is consistent with the previous conclusion that the K i for the E form of TryR is Ͼ40 M (Fig. 5C) . To confirm the validity of this 
FIG. 4. Determination of stoichiometry of alkylation by quinacrine mustard.
A sample of NADPH-reduced TryR (1 M) was inactivated by 10 M QM. The aliquots were removed at intervals and quenched with 2-mercaptoethanol, and the residual activities were determined as described in the legend to Fig. 2 . The residual activity is fitted to the equation for a single exponential decay (E). The remainder of each quenched sample was denatured with trichloroacetic acid to remove bound FAD, washed, and redissolved by proteolytic digestion. Residual covalently bound QM was determined spectrophotometrically as described under "Experimental Procedures" (q). method, a similar experiment was done with the tricyclic competitive inhibitor clomipramine (Fig. 6B) . Clomipramine strongly protected both the E and EH 2 forms from inactivation by QM, yielding K i values of 8.5 Ϯ 1.7 and 7.5 Ϯ 1.6 M, respectively. Both values are consistent with the previously reported K i of 6.5 Ϯ 0.6 M determined at pH 7.25 (38) and the value of 3.5 Ϯ 0.2 M determined via direct assay under our assay conditions (not shown). The unusual behavior of quinacrine is consistent with the ability of this inhibitor to selfassociate in solution (39) , in contrast with clomipramine.
Crystallographic Studies on Enzyme-Quinacrine Mustard Interactions-The crystal structure of QM-inactivated TryR was determined. The final model contains a TryR dimer, four quinacrine moieties, two FAD molecules, one maleic acid, and 53 ordered water molecules. Fig. 7 shows the fit of the model to the electron density, and additional details are presented in Table  I . Because the conformations and interactions in the two active sites contained in the asymmetric unit were restrained on the basis of noncrystallographic symmetry, we only provide details for one. Two molecules of the quinacrine-based inhibitor, termed Q 1 and Q 2 , are located in each active site where the substrate T[S] 2 normally binds. Both interact with residues from a single subunit (Fig. 8) figure) . At the other end of the acridine, the chlorine substituent is directed out toward solvent and is some 5.5 Å distant from any protein atoms. The acridine nitrogen is likely to be protonated and forming a hydrogen bond with OE1 of Glu 19 at a distance of 3.2 Å. The aliphatic tail of Q 1 lines up alongside the side chain of Met 114 and extends over toward a helix that lines one side of the active site. The two chlorine substituents on C-26 and C-28 have been lost by reaction with the enzyme, and covalent linkages between Q 1 and the acidic Glu 113 and Asp 117 side chains have been formed. Q 2 , as mentioned above, stacks under Q 1 and is aligned such that the acridine nitrogen and methoxy substituent are directed out away from the protein and are able to interact with water molecules. The chlorine substituent of Q 2 is placed near the tail of Q 1 and forms a hydrogen bond of length 3.0 Å with the hydroxyl group of Ser 110 . The tail of Q 2 lies along a depression formed by the side chains of Ser 15 , Tyr 111 , and Ile 339 at the base of the TryR active site. One of the chlorine substituents on the tail has been lost, and a covalent link has been formed to S ␥ of Cys 53 , part of the redox-active center of the enzyme. The other chlorine has been retained and is tucked under the ring system of Q 2 .
DISCUSSION
The previous study of Jacoby et al. (18) on a weakly diffracting monoclinic crystal form of T. cruzi TryR soaked in a quinacrine solution was limited by the poor quality of the diffraction data. Of the four active sites present in the asymmetric unit, the resulting model had only one site occupied by the ligand and this at occupancy of 0.3. These data are not publicly available, but coordinates were kindly provided by the authors for comparative purposes. Their analysis only identified a single inhibitor molecule bound near the hydrophobic pocket mainly formed by the Trp 22 and Met 114 residues. The acridine was modeled in a position perpendicular to and overlapping with Q 1 and Q 2 in our structure, with the ring nitrogen and chlorine substituent pointing toward the side chain of Trp 22 . The considerable differences observed between the two structures may However, we note that a previous kinetic analysis of several acridine derivatives indicated that more than one molecule of these inhibitors bind per TryR monomer (19) . Unfortunately these data did not allow determination of the positions or number of interaction sites, and it was assumed that one inhibitor bound in the active site in the fashion suggested in the previous model of a quinacrine complex. A second inhibitor was speculated to bind in a cavity at the dimer interface or to a hydrophobic patch at the edge of the active site. Moreover, multiple interaction sites of tricyclic molecules have been identified in a previous study that used photoaffinity labeling to examine the interaction of the tricyclic drug fluphenazine with TryR (42) . These experiments indicated multiple binding sites for tricyclic molecules in the TryR active site, yielding fluphenazine/TryR monomer molar ratios in the range of 2-5. This result was interpreted in light of the known ability of phenothiazine drugs to stack in solution, a property that they share with quinacrine (39) . Our data extend these findings by showing that the two molecules of QM that react to inactivate TryR actually bind in the active site, with no evidence for interaction elsewhere on the protein.
The observation that one of the chloroethyl groups on Q 2 is unreacted in the native protein offers an explanation for two apparent discrepancies in our biochemical and mass spectrometry studies. First, the small amount of cross-linked dimer observed only in the EH 2 form of TryR could arise during denaturation of the protein for SDS-PAGE. Second, digestion with trypsin would allow the monoalkylated peptide fragment to cross-link with other peptides in the mixture, accounting for our failure to observe the predicted products by mass spectrometry.
The structure of this QM-TryR adduct represents an end point of an alkylation reaction and might not therefore represent the actual sites for the noncovalent quinacrine interaction. However, several lines of kinetic evidence presented above indicate that the positions in which the QM are found in the crystal structure represent the actual sites at which nonreactive acridine molecules interact with TryR. Notably, the observation that a reversible EI complex (K i 36 M) is formed between QM and the EH 2 form of TryR indicates that the inhibitor does bind to the active site region. Further support for this conclusion is provided by the protection afforded by the T[S] 2 mimic, Mel T. Because it is probable that the binding mode of the arsenic-T[SH] 2 conjugate Mel T is similar to that of the natural T[S] 2 substrate, the ability of this inhibitor to protect against QM inactivation can be interpreted using the structure of the TryR-T[S] 2 complex (13). In this structure both the Q 1 -and Q 2 -binding sites are occupied by the spermidine component of the T[S] 2 substrate.
Unfortunately, the large size of the TryR substrate-binding cleft means that many different orientations of small ligands FIG. 6 . Effect of quinacrine and clomipramine on inactivation of TryR by QM. TryR (1 M) was incubated with 10 M QM, plus or minus NADPH and either quinacrine or clomipramine. The aliquots were removed at intervals, and the residual activity was determined by 100-fold dilution into assay buffer as described under "Experimental Procedures." First order rate constants were determined by nonlinear regression. A, E, plus NADPH and quinacrine; q, plus quinacrine alone. B, E, plus NADPH and clomipramine; q, plus clomipramine alone.
FIG. 7.
The difference density maps of both inhibitor molecules binding to subunit A. All atoms shown were omitted from the structure factor calculation. The density is contoured at the 1 level of that observed in the unit cell and is depicted in chicken wire; the green bonds indicate the covalent attachment between the inhibitor and the protein.
are possible. However, the synergistic effect of quinacrine on QM inactivation at low concentrations and the antagonistic effect at high concentrations clearly indicate that the two regions of the active site that bind these inhibitors can interact. This interaction appears to depend upon the planar tricyclic ring system because the competitive inhibitor clomipramine, which possesses a nonplanar ring, obeys simple one-site competitive kinetics and protects TryR against QM inactivation. These data are therefore entirely consistent with the observed QM-binding sites, which are adjacent to each other and allow stacking of the acridine ring systems.
Based on the structure of the alkylated enzyme and our kinetic data, we propose a model to explain the different effects of quinacrine and clomipramine on the QM inactivation reaction (Fig. 9) . Because inactivation of the EH 2 enzyme proceeds rapidly through the reaction of a mustard group with the Cys 53 , occupation of the Q 2 -binding site by QM will be required for this reaction to occur. However, the majority of the contacts made by the QM moiety in this position are through van der Waals' interactions with the acridine ring of the Q 1 ligand. This implies that the affinity of site Q 2 will be enhanced by an increase in the occupancy of site Q 1 . Based on the inactivation kinetics of QM with the oxidized enzyme, the affinity of this site is low (K i Ͼ 40 M) . Hence, the addition of quinacrine to a QM inactivation reaction will titrate site Q 1 and may allow more quinacrine and QM to bind to site Q 2 , thus producing an increase in the overall rate of inactivation. Because Cys 53 is only available for alkylation in the EH 2 form, enhanced inactivation is not observed in the E form. At higher concentrations of quinacrine, QM will be increasingly excluded from both sites, resulting in decreased inactivation. In contrast, the occupation of site Q 1 by clomipramine would be predicted to simultaneously reduce the occupancy of site Q 2 and thus reduce the rate of inactivation, because the nonplanar ring of this inhibitor would not allow -stacking interactions.
The description of two interacting binding sites in the active site of TryR has important implications for drug design and may allow the design of far more potent inhibitory molecules than can be produced from the simple tricyclic scaffold. This could be achieved through the design of molecules that could bind simultaneously to both of these sites. Indeed, previous studies may have unwittingly exploited this approach, for example, the finding that bis-substituted polyamine derivatives are significantly better TryR inhibitors than their monosubstituted equivalents (45) . Importantly, these polyamine derivatives include some of the most potent TryR inhibitors that have yet been described, with N 1 ,N 12 -bis-(5-bromo-3-indole acetyl)spermine having a K i of just 76 nM against T. cruzi TryR (46) . However, the The left-hand panel shows a random sequential mechanism for the formation of the doubly alkylated end product (EЈ*Q 1 *Q 2 ). The two quinacrine-binding sites are distinguished as Q 1 and Q 2 . Covalently modified sites are shown with an asterisk. E and EЈ refer to the oxidized (E) and reduced (EH 2 ) forms of the enzyme. Binding to the first site affects binding to the second site by a factor ␣. Alkylation at the Q 1 site is slow (dashed arrow) compared with the Q 2 site (bold arrow). The right-hand panel shows clomipramine overlaid on the quinacrine mustard site Q 1 to illustrate how this simple competitive inhibitor could exclude quinacrine from both binding sites. flexibility of these spermine and spermidine derivatives could produce an entropic penalty upon binding. The identification of adjacent tricyclic binding surfaces may therefore allow the construction of conformationally constrained inhibitors with affinity for both sites, resulting in even tighter binding.
Although TryR provides an attractive target for selective inhibition, purely competitive inhibitors of this enzyme may not be ideal as drug candidates, unless of low nanomolar affinity. Because there are extremely high concentrations of T[SH] 2 in the parasite cell (reaching 5 mM in Leishmania donovani (40) ), inhibition of TryR could result in the accumulation of sufficient T[S] 2 to partially reverse the effects of a competitive inhibitor (41) . Indeed, more than 90% inhibition of TryR is required to kill T. brucei (43) and L. donovani can survive an 85% reduction in TryR activity with no effect upon either their viability or their ability to metabolize H 2 O 2 (8) . Collectively, these data suggest that the ideal TryR inhibitor would be one that showed either tight binding or irreversible inhibitory activities. Although the mustard groups render QM too reactive to be considered as a lead compound, the detailed mechanistic and structural data provided in this study may allow the design of less toxic compounds with similar activities.
